Last updated: 18 September 2020 at 7:48pm EST

Sharon Stevenson Net Worth




The estimated Net Worth of Sharon Stevenson is at least $50 Tysiąc dollars as of 6 August 2019. Sharon Stevenson owns over 7,500 units of Obalon Therapeutics Inc stock worth over $50,029 and over the last 8 years he sold OBLN stock worth over $0. In addition, he makes $0 as Independent Director at Obalon Therapeutics Inc.

Sharon Stevenson OBLN stock SEC Form 4 insiders trading

Sharon has made over 1 trades of the Obalon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of OBLN stock worth $30,000 on 6 August 2019.

The largest trade he's ever made was buying 7,500 units of Obalon Therapeutics Inc stock on 6 August 2019 worth over $30,000. On average, Sharon trades about 833 units every 0 days since 2016. As of 6 August 2019 he still owns at least 18,061 units of Obalon Therapeutics Inc stock.

You can see the complete history of Sharon Stevenson stock trades at the bottom of the page.





Sharon Stevenson biography

Dr. Sharon Stevenson Ph.D. is Independent Director of the company since January 2008. Dr. Stevenson is currently a Co-Founder and Managing Director of Okapi Venture Capital, a venture capital company, where she has worked since 2005. Prior to founding Okapi, Dr. Stevenson was the Senior Vice President of Technology and Planning for SkinMedica, Inc. (acquired by Allergan, Inc.) from 2003 to 2004. Prior to SkinMedica, Dr. Stevenson was a Principal with Domain Associates, LLC from 2000 to 2003. While at Domain, Dr. Stevenson also served as President and Chief Financial Officer of Volcano Corporation. Dr. Stevenson currently serves on the board of WiserCare, Inc., BioTrace Medical, Inc. and Focal Therapeutics, Inc., and has previously served on the board of directors of Helixis, Inc. (acquired by Illumina), OrthAlign, Inc. and PathCentral, Inc. Dr. Stevenson holds a Master of Science in Veterinary Pathology and Doctor of Veterinary Medicine from The Ohio State University, an M.B.A from the UCLA Anderson Graduate School of Management and a Ph.D. in Comparative Pathology from the University of California, Davis. Our board of directors believes that Dr. Stevenson’s extensive industry experience and experience advising medical aesthetic companies qualifies her to serve on our board of directors.



How old is Sharon Stevenson?

Sharon Stevenson is 67, he's been the Independent Director of Obalon Therapeutics Inc since 2008. There are 2 older and 11 younger executives at Obalon Therapeutics Inc. The oldest executive at Obalon Therapeutics Inc is Raymond Dittamore, 73, who is the Independent Director.

What's Sharon Stevenson's mailing address?

Sharon's mailing address filed with the SEC is C/O OKAPI VENTURE CAPITAL, 1590 SOUTH COAST HIGHWAY, NO. 10, LAGUNA BEACH, CA, 92651.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... oraz David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.



What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.



What does Obalon Therapeutics Inc's logo look like?

Obalon Therapeutics Inc logo

Complete history of Sharon Stevenson stock trades at Obalon Therapeutics Inc

Data
#
Firma
Osoba
Trans.
Transakcja
Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
6 Aug 2019 Sharon Stevenson
Kupować 7,500 $4.00 $30,000
6 Aug 2019
18,061


Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include: